
Tempest Therapeutics, Inc.
96
Recent developments highlight strategic acquisition completion, clinical pipeline advancements, financial results, and regulatory notices impacting the company’s operational and market status.
- Tempest announced the closing of its strategic acquisition of dual-targeting CAR-T assets in February 2026, expanding its cell therapy portfolio [N5].
- The company reported narrowing Q2 losses and advancement of its in vivo CAR-T pipeline with candidate TPST-4003 as of August 2026 [N3].
- Tempest received a Nasdaq notice in November 2026 for its common stock bid price falling below $1.00, triggering a compliance period to regain listing standards [N1].
- The company is pursuing business development discussions to advance pivotal development of amezalpat for hepatocellular carcinoma [N2].
Tempest Therapeutics operates as a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. Its cell therapy pipeline includes autologous, allogeneic, and in vivo dual-targeting CAR-T therapies designed to address hematologic malignancies, solid tumors, and immunology indications. The lead CAR-T candidate, TPST-2003, targets CD19 and BCMA for relapsed or refractory multiple myeloma and is in Phase 1/2 clinical trials. The small molecule pipeline includes amezalpat, Phase 3-ready for first-line hepatocellular carcinoma, and TPST-1495, planned for Phase 2 study in familial adenomatous polyposis with external funding. The company pursues a capital-efficient development strategy leveraging partnerships and external funding to extend its operational runway. Recent strategic acquisition expanded its CAR-T portfolio. Financially, the company reported a net loss and liquidity constraints as of Q3 2026. Nasdaq listing compliance risks and management turnover are notable challenges.
Tempest Therapeutics, Inc. is a clinical-stage biotech company focused on developing a diversified portfolio of cell therapy and small molecule candidates targeting cancers and immunology indications. The company’s pipeline includes dual-targeting CAR-T therapies such as TPST-2003 for relapsed or refractory multiple myeloma and small molecules like amezalpat for hepatocellular carcinoma and TPST-1495 for familial adenomatous polyposis. Recent strategic acquisition expanded its CAR-T portfolio. Financially, as of September 30, 2026, the company reported a net loss of $3.63 million and liquidity ratios indicating limited current asset coverage of liabilities. The company faces Nasdaq listing compliance risks due to low stockholders’ equity and bid price. Management turnover and governance changes present additional operational risks. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company’s dual-targeting CAR-T therapies, including TPST-2003, have demonstrated promising early clinical responses with a favorable safety profile, potentially addressing limitations of current single-target CAR-T therapies. Positive Phase 2 data and regulatory designations for amezalpat support its advancement toward pivotal development. External funding for TPST-1495’s Phase 2 trial reduces capital burden. Strategic acquisitions and partnerships enhance pipeline breadth and capital efficiency. These factors collectively support the company’s potential to develop differentiated therapies addressing significant unmet medical needs in oncology and immunology.
The company faces significant financial challenges, including a net loss and liquidity constraints with a current ratio below 1, raising concerns about its ability to sustain operations without additional funding. Nasdaq listing compliance risks due to low stockholders’ equity and bid price may impact market liquidity and investor confidence. Management and board turnover pose governance and execution risks. Clinical programs remain early-stage with limited patient data, and the success of novel dual-targeting CAR-T therapies and small molecules is uncertain. Failure to secure partnerships or funding could delay development and commercialization efforts.
Tempest Therapeutics’ moat is based on its diversified pipeline of innovative dual-targeting CAR-T therapies and first-in-class small molecule candidates addressing high unmet medical needs in oncology and immunology. Its strategic acquisition of dual-targeting CAR-T assets and partnerships for clinical development provide access to novel modalities and potential scalability advantages. Regulatory designations such as orphan drug and fast track status for key candidates may offer development and market exclusivity benefits. However, as a clinical-stage company without approved products, its moat depends on successful clinical advancement and regulatory approvals amid competitive and scientific risks.
• Financial and Liquidity Risks: The company reported a net loss of $3.63 million for Q3 2026 and has a current ratio of 0.34, indicating limited current asset coverage of liabilities. It requires significant additional funding to continue operations, with substantial doubt about its ability to continue as a going concern [S2].
• Nasdaq Listing Compliance Risks: Tempest received notices for non-compliance with Nasdaq’s minimum stockholders’ equity and minimum bid price requirements, with risk of delisting if compliance is not regained by specified deadlines [S2][N1].
• Management and Governance Risks: Significant turnover in senior management and board members, including CFO changes, may disrupt strategic execution, weaken controls, and impair the company’s ability to attract and retain qualified personnel [S2].
• Clinical and Development Risks: Clinical programs are in early stages with limited patient data. The safety and efficacy of novel dual-targeting CAR-T therapies and small molecules remain to be established in larger trials. Regulatory approvals and successful commercialization are uncertain [S1].
• Capital Efficiency and Funding Risks: The company’s strategy relies on partner support and external funding to extend operational runway. Failure to secure such support could limit development progress and increase capital requirements [S1].
Business trends: Advancement of dual-targeting CAR-T therapies and small molecule candidates with regulatory designations and strategic acquisitions expanding pipeline.
Execution milestones: Completion of strategic CAR-T asset acquisition, ongoing clinical trials including Phase 1/2 studies, and pursuit of pivotal development partnerships.
Key risks: Financial liquidity constraints, Nasdaq listing compliance risks, management turnover, and clinical development uncertainties inherent to early-stage biotech.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates [S1].
- In February 2026, Tempest acquired rights to a portfolio of dual-targeting CAR-T product candidates, including TPST-2003, an autologous CD19/BCMA CAR-T therapy in clinical development for relapsed or refractory multiple myeloma (rrMM) [S1].
- The company’s pipeline includes autologous, allogeneic, and in vivo CAR-T therapies targeting hematologic malignancies, solid tumors, and immunology indications [S1].
- Small molecule candidates include amezalpat (TPST-1120), Phase 3-ready for first-line hepatocellular carcinoma (HCC), and TPST-1495, planned for Phase 2 study in familial adenomatous polyposis (FAP) with NCI funding [S1].
- Amezalpat showed positive Phase 2 data with a six-month median overall survival improvement in combination with atezolizumab and bevacizumab in unresectable/metastatic HCC [S1].
- FDA granted orphan drug designation and fast track designation to amezalpat for HCC; EMA also granted orphan drug designation [S1].
- TPST-1495 is a dual antagonist targeting EP2 and EP4 receptors of prostaglandin E2, implicated in multiple cancers and FAP; a Phase 2 trial is authorized and expected to begin in 2026 [S1].
- TPST-2003 is being evaluated in Phase 1/2 investigator-initiated and REDEEM-1 Phase 1/2a trials in rrMM; early data show 100% overall response rate among evaluable patients [S1].
- Safety profile of TPST-2003 includes no Grade 3 or higher cytokine release syndrome and limited neurotoxicity [S1].
- The company completed a strategic acquisition of dual-targeting CAR-T assets in February 2026, issuing 8,268,495 shares to Erigen LLC [S1][N5].
- Tempest pursues a capital-efficient development strategy including partner support and external funding to extend operational runway [S1].
- Financial snapshot as of September 30, 2026: cash and equivalents $897,000; current assets $1,609,000; current liabilities $4,669,000; net loss $3,629,000 for the quarter; basic and diluted EPS -$0.21 [S2].
- Liquidity ratios as of September 30, 2026: current ratio 0.34, cash ratio 3.28 [S2].
- The company has received Nasdaq notices for non-compliance with minimum stockholders’ equity and minimum bid price requirements, with risk of delisting [S2][N1].
- Significant board and management turnover has occurred, including CFO changes, posing continuity and governance risks [S2].
- Recent developments include narrowing Q2 loss and advancement of in vivo CAR-T pipeline with TPST-4003 [N3].
- Tempest announced closing of strategic acquisition of dual-targeting CAR-T assets in February 2026 [N5].
- The company received Nasdaq notice of bid price below $1.00 in November 2026 [N1].
- Tempest is pursuing business development discussions to advance pivotal development of amezalpat [N2].
Generated 2026-11-14
- S1 | 2026-03-30 | 10-K
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-11-06 | www.nasdaq.com | Tempest Therapeutics Receives Nasdaq Notice of Bid Price Below $1.00 | https://www.nasdaq.com/articles/tempest-therapeutics-receives-nasdaq-notice-bid-price-below-100
- N2 | 2026-09-16 | www.nasdaq.com | Biotech Stocks See Fresh Catalysts: Tempest, DataMEDS, NeurAxis & MAIA | https://www.nasdaq.com/articles/biotech-stocks-see-fresh-catalysts-tempest-datameds-neuraxis-maia
- N3 | 2026-08-17 | www.nasdaq.com | Tempest Q2 Loss Narrows; Advances In Vivo CAR-T Pipeline With TPST-4003 | https://www.nasdaq.com/articles/tempest-q2-loss-narrows-advances-vivo-car-t-pipeline-tpst-4003
- N4 | 2026-06-30 | www.nasdaq.com | Rani Therapeutics Appoints Nicholas Maestas CFO Following Sanford Departure | https://www.nasdaq.com/articles/rani-therapeutics-appoints-nicholas-maestas-cfo-following-sanford-departure
- N5 | 2026-02-04 | www.globenewswire.com | Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets | https://globenewswire.com/news-release/2026/02/04/3232545/0/en/Tempest-Announces-Closing-of-Strategic-Acquisition-of-Dual-Targeting-CAR-T-Assets.html
- N6 | 2026-01-20 | www.globenewswire.com | Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders | https://www.globenewswire.com/news-release/2026/01/20/3222341/0/en/Tempest-Announces-Record-Date-for-Anticipated-Dividend-Distribution-of-Warrants-to-Stockholders.html
- N7 | 2025-06-30 | www.nasdaq.com | Tempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China | https://www.nasdaq.com/articles/tempest-therapeutics-receives-nmpa-approval-pivotal-trial-amezalpat-hepatocellular
- N8 | 2025-06-12 | www.nasdaq.com | Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor | https://www.nasdaq.com/articles/tempest-therapeutics-announces-46-mln-registered-direct-offering-institutional-investor
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


